There are currently 15 active clinical trials seeking participants for Systemic Sclerosis research studies. The states with the highest number of trials for Systemic Sclerosis participants are California, New York, Texas and Pennsylvania.
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Participants With Immune-Mediated Diseases (Ntrust-2)
NCT06733935
Recruiting
This is an open-label, multi-center, multi-cohort, non-randomized Phase 1 study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with Immune-Mediated Diseases (IMD) including systemic sclerosis \[SSc\], idiopathic inflammatory myopathies \[IIM\], and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis \[AAV\].
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/18/2025
Locations: Nkarta Investigational Site, Orange, California +9 locations
Conditions: Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Register for Updates
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803
Recruiting
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/14/2025
Locations: Research Site, Birmingham, Alabama +198 locations
Conditions: Systemic Sclerosis, Scleroderma
Register for Updates
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT06925542
Recruiting
This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/08/2025
Locations: Research Site 4, Redwood City, California +7 locations
Conditions: SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy, Idiopathic, Myositis, Diffuse Cutaneous Systemic Sclerosis
Register for Updates
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
NCT05869955
Recruiting
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +53 locations
Conditions: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis
Register for Updates
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
NCT07085104
Recruiting
This is a first-in-human, single-arm, open-label study evaluating the safety, tolerability, and preliminary efficacy of ALLO-329 in adults with autoimmune diseases: systemic lupus erythematosus (SLE) with and without renal involvement, idiopathic inflammatory myopathy (IIM), and systemic sclerosis (SSc).The purpose of this trial is to evaluate the safety and tolerability of ALLO-329, an allogeneic anti-CD19, anti-CD70 dual chimeric antigen receptor (CAR) T cell therapy, in adults with autoimmune... Read More
Gender:
ALL
Ages:
Between 18 years and 69 years
Trial Updated:
07/23/2025
Locations: Astera Cancer Care, East Brunswick, New Jersey +1 locations
Conditions: Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Lupus Nephritis
Register for Updates
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
NCT06434363
Recruiting
The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and lymphodepleting chemotherapy that can be given to patients with the disease. The goal of Phase 2 is to learn if the dose of AD-PluReceptor-NK cells found in Phase 1 in combination with tafasitamab and lymphodepleting chemotherapy can help to control the disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Autoimmune Disorders, Systemic Sclerosis, Systemic Lupus Erythematosus, Lupus, Lupus Nephritis
Register for Updates
Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis
NCT05989763
Recruiting
The purpose of this study is to determine whether transcutaneous electrical acustimulation (TEA) alters systemic sclerosis (SSc)-related colonic and anorectal physiology by enhancing autonomic nervous system (ANS) function. The study will examine the effects of TEA on slow colonic transit (SCT) and rectal hyposensitivity (RH), to examine whether TEA improves autonomic dysfunction and modulates inflammatory pathways.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Systemic Sclerosis, Constipation, Gastrointestinal Motility Disorder, Autonomic Dysfunction
Register for Updates
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
NCT06328777
Recruiting
RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/20/2025
Locations: Yale University, New Haven, Connecticut +9 locations
Conditions: Systemic Sclerosis, Scleroderma
Register for Updates
A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease
NCT06544330
Recruiting
This is a phase 1 study of SYNCAR-001 + STK-009 in patients with severe, refractory systemic autoimmune rheumatic disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: HonorHealth Research Institute, Scottsdale, Arizona +4 locations
Conditions: Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis
Register for Updates
Autologous Stem Cell Transplantation in Patients with Systemic Sclerosis
NCT03630211
Recruiting
The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect.
Gender:
ALL
Ages:
Between 8 years and 60 years
Trial Updated:
03/13/2025
Locations: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania +2 locations
Conditions: Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
Register for Updates
Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
NCT03844061
Recruiting
This is a 52 week, single center, randomized, double-blind, placebo-controlled study. After patients maintain a stable dose of Mycophenolate Mofetil (MMF) for at least 1 month, they will be randomized to treatment with either Belimumab \& Rituximab or placebo.Patients in both groups will be on background MMF for the entirety of the study. Belimumab will be administered subcutaneously and Rituximab intravenously. Placebo injections and infusions will be of normal saline. Randomization will be do... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/12/2025
Locations: Hospital for Special Surgery, New York, New York
Conditions: Systemic Sclerosis
Register for Updates
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
NCT05029336
Recruiting
A subset of autoimmune diseases (ADs) in children and young adults are life-threatening and unresponsive to conventional treatments. In these patients, the delivery of high dose immunosuppressive therapy followed by autologous stem cell transplant (ASCT) offers a treatment strategy capable of purging the pathogenic, autoreactive immune system and an opportunity for "immune reset." This strategy has been used in adults across a myriad of indications with evidence for efficacy. This study proposes... Read More
Gender:
ALL
Ages:
Between 8 years and 25 years
Trial Updated:
03/04/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Systemic Lupus Erythematosus, Systemic Sclerosis
Register for Updates